Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05), Zacks reports. Aquestive Therapeutics updated its FY 2025 guidance to EPS.
Aquestive Therapeutics Price Performance
NASDAQ:AQST traded up $0.06 on Wednesday, hitting $2.79. 1,379,107 shares of the company’s stock were exchanged, compared to its average volume of 1,764,951. The firm has a 50-day moving average price of $3.14 and a 200-day moving average price of $4.14. Aquestive Therapeutics has a 52 week low of $2.24 and a 52 week high of $6.23. The company has a market cap of $254.39 million, a P/E ratio of -6.20 and a beta of 2.76.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on AQST shares. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $11.00.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Further Reading
- Five stocks we like better than Aquestive Therapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Stock Market Upgrades: What Are They?
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- What is a Low P/E Ratio and What Does it Tell Investors?
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
